Skip to main content

Table 5 Association between first breast cancer HR status and subtype-specific CBC, among known BRCA1/2 mutation non-carriers

From: Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

  Overall CBC ER+/PR+ CBC ER+/PR- CBC ER-/PR- CBC
N (cases/controls) RRa (95% CI) RRb (95% CI) N (cases/controls) RRa (95% CI) RRb (95% CI) N (cases/controls) RRa (95% CI) RRb (95% CI) N (cases/controls) RRa (95% CI) RRb (95% CI)
All women tested for BRCA1/2 mutationsc, tumor status at first diagnosis
 ER status
  Positive 336/745 1.0 (ref.) 1.0 (ref.) 100/179 1.0 (ref.) 1.0 (ref.) 41/66 1.0 (ref.) 1.0 (ref.) 26/114 1.0 (ref.) 1.0 (ref.)
  Negative 193/338 1.4 (1.1, 1.9) 1.2 (0.9, 1.6) 22/82 0.6 (0.3, 1.2) 0.7 (0.3, 1.3) 15/31 0.8 (0.3, 2.0) 0.8 (0.3, 2.0) 56/56 4.6 (2.1, 10.2) 3.8 (1.6, 8.9)
  Other/unknownd 176/315    33/44    9/30    19/32   
 PR status
  Positive 287/615 1.0 (ref.) 1.0 (ref.) 88/160 1.0 (ref.) 1.0 (ref.) 35/61 1.0 (ref.) 1.0 (ref.) 23/95 1.0 (ref.) 1.0 (ref.)
  Negative 172/318 1.3 (1.0, 1.7) 1.1 (0.8, 1.5) 26/86 0.8 (0.4, 1.5) 0.8 (0.5, 1.5) 16/20 2.2 (0.7, 6.8) 2.2 (0.7, 6.8) 56/55 5.3 (2.3, 12.2) 6.8 (2.6, 17.6)
  Other/unknownd 246/465    41/59    14/46    22/52   
 Joint ER/PR status
  ER+/PR+ 250/536 1.0 (ref.) 1.0 (ref.) 84/143 1.0 (ref.) 1.0 (ref.) 29/46 1.0 (ref.) 1.0 (ref.) 16/86 1.0 (ref.) 1.0 (ref.)
  ER+/PR- 38/85 1.1 (0.7, 1.7) 1.1 (0.7, 1.7) 9/22 0.9 (0.3, 2.3) 0.8 (0.3, 2.2) 7/4 4.9 (0.9, 26.5) 5.0 (0.9, 27.3) 8/14 4.6 (1.3, 16.4) 5.3 (1.3, 21.5)
  ER-/PR- 132/221 1.5 (1.1, 2.1) 1.2 (0.9, 1.7) 17/61 0.7 (0.3, 1.5) 0.8 (0.4, 1.6) 9/16 1.2 (0.3, 4.7) 1.2 (0.3, 4.6) 48/41 7.6 (3.0, 19.5) 8.9 (3.1, 25.9)
  Other/unknownd.e 285/556    45/79    20/61    29/61   
BRCA1/2 non-carriers only, tumor status at first diagnosis
 ER status
  Positive 307/716 1.0 (ref.)   89/178 1.0 (ref.)   39/64 1.0 (ref.)   23/106 1.0 (ref.)  
  Negative 137/304 1.2(0.9, 1.7)   19/70 0.7 (0.3, 1.5)   12/29 0.4 (0.1, 1.4)   33/52 3.6 (1.4, 8.9)  
  Other/unknownd 152/302    30/42    9/29    14/32   
 PR status
  Positive 261/593 1.0 (ref.)   81/159 1.0 (ref.)   32/59 1.0 (ref.)   18/88 1.0 (ref.)  
  Negative 122/286 1.0 (0.8, 1.4)   21/75 0.8 (0.4, 1.7)   14/19 1.6 (0.5, 5.3)   36/52 6.7 (2.4, 18.9)  
  Other/unknownd 213/443    36/56    14/44    16/50   
 Joint ER/PR status
  ER+/PR+ 233/520 1.0 (ref.)   77/143 1.0 (ref.)   27/45 1.0 (ref.)   15/80 1.0 (ref.)  
  ER+/PR- 31/78 0.9 (0.5, 1.4)   7/22 0.7 (0.2, 2.0)   7/4 4.4 (0.8, 23.6)   6/13 3.8 (0.8, 17.2)  
  ER-/PR- 90/197 1.2 (0.8, 1.8)   14/50 0.9 (0.4, 2.0)   7/15 0.6 (0.1, 2.8)   30/39 7.7 (2.6, 23.3)  
  Other/unknownd,e 242/527    40/75    19/58    19/58   
  1. Abbreviations: HR, hormone receptor, CBC contralateral breast cancer, N number, RR risk ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor. aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, menopausal status, age at menarche, parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. bAdjusted for all covariates listed in footnote a and in addition BRCA1 deleterious mutation status. c BRCA1/2 mutation status only assessed among women sampled in the first phase of the Women’s Environmental Cancer and Radiation Epidemiology Study (WECARE) I. d“Other/unknown” category consists of women for whom no laboratory test was given, the test was given and the results were unknown or the test was given and the results were borderline; estimates not reported. eIncludes tumors classified as ER-/PR+